---
title: "Pediatric Infectious Diseases"
order: 2
category: "Pediatrics"
---

# Pediatric Infectious Diseases

## Overview

Infectious diseases remain a major cause of morbidity and mortality in children worldwide, despite significant advances in prevention through vaccination and improvements in hygiene and sanitation. Children are particularly susceptible to infections due to immature immune systems, close contact in childcare and school settings, and frequent hand-to-mouth activity. Understanding common pediatric infections, their clinical presentations, and evidence-based management is essential for all healthcare providers caring for children.

**Key Concept**: Pediatric infectious diseases often present differently than in adults, with age-specific considerations for diagnosis, treatment, and prevention being paramount.

### Epidemiology
- **Prevalence**: Children average 6-8 respiratory infections per year
- **Impact**: Leading cause of healthcare visits and antibiotic prescriptions
- **Prevention**: Immunizations have dramatically reduced vaccine-preventable diseases
- **Global burden**: Infections remain leading cause of child mortality worldwide
- **Antimicrobial resistance**: Growing concern in pediatric populations

### Unique Pediatric Considerations
- **Immature immunity**: Developing immune system increases susceptibility
- **Vaccine-preventable diseases**: Comprehensive immunization schedules
- **Contagion**: Close contact in schools and daycare facilitates transmission
- **Dosing challenges**: Weight-based dosing, limited formulations
- **Communication**: Reliance on caregivers for history

## Principles of Pediatric Infectious Disease Management

### Diagnostic Approach
- **Clinical assessment**: Age-specific presentations and vital signs
- **Focused examination**: Identify source of infection
- **Appropriate testing**: Selective use of laboratory studies
- **Consider age**: Neonates and young infants require different approach
- **Immunization status**: Review vaccination history

### Treatment Principles
- **Appropriate antibiotics**: Use only when bacterial infection likely
- **Weight-based dosing**: Accurate weight measurement essential
- **Narrow spectrum**: Use narrowest effective antibiotic
- **Adequate duration**: Complete prescribed course
- **Supportive care**: Hydration, fever management, symptom relief

### Prevention Strategies
- **Immunizations**: Follow CDC/AAP recommended schedule
- **Hand hygiene**: Most important infection prevention measure
- **Respiratory etiquette**: Cover coughs and sneezes
- **Exclusion policies**: Keep sick children home from school/daycare
- **Environmental measures**: Cleaning, ventilation

## Immunizations

### Vaccine Schedule Overview (CDC 2024)

#### Birth
- **Hepatitis B**: First dose (HepB #1)

#### 2 Months
- **DTaP**: Diphtheria, tetanus, pertussis #1
- **IPV**: Inactivated polio #1
- **Hib**: Haemophilus influenzae type b #1
- **PCV**: Pneumococcal conjugate #1
- **HepB**: Hepatitis B #2
- **Rotavirus**: #1

#### 4 Months
- **DTaP**: #2
- **IPV**: #2
- **Hib**: #2
- **PCV**: #2
- **Rotavirus**: #2

#### 6 Months
- **DTaP**: #3
- **IPV**: #3 (6-18 months)
- **Hib**: #3
- **PCV**: #3
- **HepB**: #3 (6-18 months)
- **Rotavirus**: #3 (if applicable)
- **Influenza**: Annual, starting at 6 months

#### 12-15 Months
- **MMR**: Measles, mumps, rubella #1
- **Varicella**: Chickenpox #1
- **Hib**: #4
- **PCV**: #4
- **HepA**: Hepatitis A #1

#### 15-18 Months
- **DTaP**: #4

#### 18 Months
- **HepA**: #2 (6-18 months after #1)

#### 4-6 Years
- **DTaP**: #5
- **IPV**: #4
- **MMR**: #2
- **Varicella**: #2

#### 11-12 Years
- **Tdap**: Tetanus, diphtheria, pertussis booster
- **HPV**: Human papillomavirus (2 or 3 doses)
- **MenACWY**: Meningococcal conjugate #1

#### 16 Years
- **MenACWY**: #2
- **MenB**: Meningococcal B (optional, 2 doses)

### Vaccine Principles

#### Vaccine Types
- **Live attenuated**: MMR, varicella, rotavirus, intranasal influenza
- **Inactivated**: DTaP, IPV, hepatitis A
- **Subunit/conjugate**: Hib, PCV, HPV, MenACWY
- **Toxoid**: Tetanus, diphtheria

#### Administration
- **Route**: Intramuscular (most), subcutaneous (MMR, varicella), oral (rotavirus)
- **Site**: Anterolateral thigh (<12 months), deltoid (>12 months)
- **Timing**: Minimum intervals between doses
- **Simultaneous administration**: Multiple vaccines can be given same day

#### Contraindications and Precautions
- **Severe allergic reaction**: To vaccine component or previous dose
- **Moderate-to-severe illness**: Delay until recovered
- **Live vaccines in immunocompromised**: Generally contraindicated
- **Pregnancy**: Avoid live vaccines
- **Recent immunoglobulin**: May interfere with live vaccines

#### Vaccine Safety
- **Surveillance systems**: VAERS, VSD
- **Common reactions**: Local soreness, low-grade fever
- **Serious adverse events**: Rare (anaphylaxis 1 in 1 million)
- **Autism**: No link between vaccines and autism (extensively studied)

## Vaccine-Preventable Diseases

### Measles (Rubeola)

#### Virology
- **Virus**: Paramyxovirus, highly contagious
- **Transmission**: Airborne, respiratory droplets
- **Incubation**: 10-14 days
- **Contagious period**: 4 days before to 4 days after rash onset

#### Clinical Presentation
- **Prodrome**: 3-5 days of high fever, cough, coryza, conjunctivitis (3 C's)
- **Koplik spots**: White spots on buccal mucosa, pathognomonic
- **Rash**: Maculopapular, starts at hairline, spreads downward
- **Course**: Rash lasts 5-6 days, desquamation follows

#### Complications
- **Otitis media**: Most common complication
- **Pneumonia**: Leading cause of measles deaths
- **Encephalitis**: 1 in 1,000 cases
- **SSPE**: Subacute sclerosing panencephalitis (rare, late complication)
- **Death**: 1-2 per 1,000 cases in developed countries

#### Management
- **Supportive care**: Hydration, fever management
- **Vitamin A**: Recommended by WHO, reduces complications
- **Isolation**: Airborne precautions
- **Post-exposure prophylaxis**: MMR within 72 hours or Ig within 6 days

### Mumps

#### Virology
- **Virus**: Paramyxovirus
- **Transmission**: Respiratory droplets, direct contact with saliva
- **Incubation**: 16-18 days (range 12-25 days)
- **Contagious period**: 2 days before to 5 days after parotitis onset

#### Clinical Presentation
- **Parotitis**: Bilateral (75%) or unilateral parotid swelling
- **Prodrome**: Fever, headache, myalgia, anorexia
- **Pain**: Earache, pain with chewing
- **Duration**: Swelling peaks at 1-3 days, resolves in 7-10 days

#### Complications
- **Orchitis**: 20-30% of post-pubertal males, rarely causes sterility
- **Oophoritis**: 5% of post-pubertal females
- **Meningitis**: 10-15% (usually benign)
- **Encephalitis**: Rare but serious
- **Pancreatitis**: Uncommon
- **Deafness**: Permanent unilateral hearing loss (rare)

#### Management
- **Supportive care**: Analgesics, hydration
- **Isolation**: Droplet precautions for 5 days after onset
- **Complications**: Monitor for CNS involvement, orchitis

### Rubella (German Measles)

#### Virology
- **Virus**: Togavirus
- **Transmission**: Respiratory droplets
- **Incubation**: 14-21 days
- **Contagious period**: 7 days before to 7 days after rash

#### Clinical Presentation
- **Mild illness**: Often subclinical in children
- **Prodrome**: Low-grade fever, malaise, lymphadenopathy
- **Lymphadenopathy**: Posterior auricular, occipital (characteristic)
- **Rash**: Pink maculopapular, starts on face, spreads downward
- **Duration**: Rash lasts 3 days ("3-day measles")

#### Complications
- **Arthralgia/arthritis**: Common in adolescents and adults
- **Thrombocytopenia**: Rare
- **Encephalitis**: Very rare
- **Congenital rubella syndrome**: Major concern if infection during pregnancy

#### Congenital Rubella Syndrome
- **Triad**: Cataracts, deafness, cardiac defects
- **Other manifestations**: Microcephaly, intellectual disability, growth restriction
- **Risk**: Highest in first trimester (>80% if <12 weeks)
- **Prevention**: Ensure immunity before pregnancy

### Pertussis (Whooping Cough)

#### Bacteriology
- **Organism**: Bordetella pertussis (gram-negative coccobacillus)
- **Transmission**: Respiratory droplets, highly contagious
- **Incubation**: 7-10 days (range 4-21 days)
- **Contagious period**: Most contagious during catarrhal stage

#### Clinical Presentation

##### Catarrhal Stage (1-2 weeks)
- **Symptoms**: Rhinorrhea, mild cough, low-grade fever
- **Appearance**: Looks like common cold
- **Most contagious**: Highest transmission during this stage

##### Paroxysmal Stage (2-6 weeks)
- **Paroxysms**: Severe coughing fits
- **Whoop**: Inspiratory whoop after coughing fit
- **Post-tussive emesis**: Vomiting after coughing
- **Apnea**: Especially in young infants

##### Convalescent Stage (weeks to months)
- **Gradual improvement**: Cough slowly resolves
- **Prolonged course**: May last several months
- **Recurrence**: Cough may recur with subsequent respiratory infections

#### Complications
- **Pneumonia**: Secondary bacterial infection
- **Seizures**: Hypoxia-related
- **Encephalopathy**: Rare but serious
- **Death**: Highest risk in infants <6 months
- **Other**: Rib fractures, hernias, rectal prolapse from coughing

#### Diagnosis
- **Clinical**: Classic presentation in unvaccinated child
- **PCR**: Most sensitive in early disease
- **Culture**: Gold standard but slow, declining sensitivity
- **Serology**: Limited use in acute diagnosis

#### Management
- **Antibiotics**: Azithromycin (macrolide) if <3 weeks from onset
- **Supportive care**: Hydration, oxygen, hospitalization for severe cases
- **Isolation**: Droplet precautions for 5 days after starting antibiotics
- **Post-exposure prophylaxis**: Antibiotics for close contacts

### Varicella (Chickenpox)

#### Virology
- **Virus**: Varicella-zoster virus (VZV, herpesvirus)
- **Transmission**: Airborne, direct contact with lesions
- **Incubation**: 14-16 days (range 10-21 days)
- **Contagious period**: 1-2 days before rash until all lesions crusted

#### Clinical Presentation
- **Prodrome**: Fever, malaise 1-2 days before rash
- **Rash**: Starts on face/trunk, spreads to extremities
- **Progression**: Macules → papules → vesicles → crusts ("dewdrop on rose petal")
- **Lesions**: Different stages simultaneously (polymorphic)
- **Pruritus**: Intense itching
- **Duration**: New lesions for 3-5 days, all crusted by 6-7 days

#### Complications
- **Bacterial superinfection**: Cellulitis, abscess (group A strep, staph)
- **Pneumonia**: More common in adults
- **Encephalitis**: 1 in 40,000 cases
- **Cerebellar ataxia**: Usually resolves completely
- **Reye syndrome**: Associated with aspirin use (avoid aspirin)
- **Congenital varicella**: If maternal infection in first half of pregnancy
- **Neonatal varicella**: Severe if maternal infection 5 days before to 2 days after delivery

#### Management
- **Supportive care**: Antihistamines for itching, acetaminophen for fever
- **Antiviral therapy**: Acyclovir for high-risk patients
- **Infection prevention**: Keep fingernails short, avoid scratching
- **Isolation**: Airborne and contact precautions

#### Post-Exposure Prophylaxis
- **Varicella vaccine**: Within 3-5 days for susceptible individuals
- **VariZIG**: Varicella-zoster immune globulin for high-risk exposed individuals
- **Acyclovir**: Prophylaxis for immunocompromised

### Diphtheria

#### Bacteriology
- **Organism**: Corynebacterium diphtheriae (gram-positive rod)
- **Toxin**: Exotoxin inhibits protein synthesis
- **Transmission**: Respiratory droplets, direct contact
- **Incubation**: 2-5 days

#### Clinical Presentation
- **Pharyngeal diphtheria**: Sore throat, low-grade fever
- **Pseudomembrane**: Gray adherent membrane on tonsils/pharynx
- **Bull neck**: Cervical lymphadenopathy and edema
- **Laryngeal involvement**: Hoarseness, stridor, respiratory obstruction

#### Complications
- **Myocarditis**: Can cause heart failure, arrhythmias
- **Neuropathy**: Cranial nerves, then peripheral nerves
- **Respiratory obstruction**: From membrane or laryngeal involvement
- **Death**: 5-10% mortality despite treatment

#### Diagnosis
- **Clinical**: Pseudomembrane highly suggestive
- **Culture**: Special media required
- **PCR**: Available in some centers

#### Management
- **Antitoxin**: Diphtheria antitoxin immediately (don't wait for culture)
- **Antibiotics**: Erythromycin or penicillin
- **Supportive care**: Airway management, cardiac monitoring
- **Isolation**: Droplet precautions
- **Contacts**: Prophylactic antibiotics, booster immunization

### Tetanus

#### Bacteriology
- **Organism**: Clostridium tetani (gram-positive anaerobic rod)
- **Spores**: Ubiquitous in soil, feces
- **Toxin**: Tetanospasmin blocks inhibitory neurotransmitters
- **Entry**: Through wounds, particularly puncture wounds

#### Clinical Presentation
- **Trismus**: Lockjaw, inability to open mouth
- **Risus sardonicus**: Facial muscle spasm ("sardonic smile")
- **Opisthotonus**: Arching of back
- **Generalized spasms**: Triggered by stimuli (noise, light, touch)
- **Autonomic instability**: Labile blood pressure, tachycardia

#### Management
- **Airway**: Intubation often necessary
- **Tetanus immune globulin**: Neutralize unbound toxin
- **Antibiotics**: Metronidazole or penicillin
- **Muscle relaxants**: Control spasms
- **Supportive care**: ICU care, minimize stimulation
- **Wound care**: Debridement

#### Prevention
- **Immunization**: DTaP series, Td/Tdap boosters every 10 years
- **Wound management**: Clean wounds, consider Td booster and TIG based on immunization history

### Poliomyelitis

#### Virology
- **Virus**: Poliovirus (enterovirus)
- **Transmission**: Fecal-oral route
- **Incubation**: 7-14 days
- **Status**: Eradicated in most countries through vaccination

#### Clinical Presentation
- **Asymptomatic**: 90-95% of infections
- **Abortive polio**: Fever, malaise, sore throat (4-8%)
- **Non-paralytic**: Aseptic meningitis (1-2%)
- **Paralytic**: Asymmetric flaccid paralysis (0.1-2%)

#### Paralytic Polio
- **Spinal**: Asymmetric flaccid paralysis of limbs
- **Bulbar**: Cranial nerve involvement, respiratory failure
- **Residual**: Permanent paralysis in many survivors

#### Prevention
- **IPV**: Inactivated polio vaccine (used in US)
- **OPV**: Oral polio vaccine (used in eradication programs)
- **Eradication efforts**: Wild polio nearly eradicated globally

## Childhood Exanthems

### Roseola Infantum (Sixth Disease)

#### Virology
- **Virus**: Human herpesvirus 6 (HHV-6)
- **Age**: Typically 6 months to 2 years
- **Transmission**: Saliva, respiratory secretions

#### Clinical Presentation
- **High fever**: Sudden onset, 39-40°C (102-104°F) for 3-5 days
- **Well appearance**: Child appears well despite high fever
- **Rash**: Appears as fever resolves (fever then rash)
- **Rash characteristics**: Pink maculopapular, starts on trunk, spreads to extremities
- **Duration**: Rash lasts 1-2 days

#### Complications
- **Febrile seizures**: Most common complication (10-15%)
- **Encephalitis**: Rare

#### Management
- **Supportive care**: Antipyretics, hydration
- **Reassurance**: Benign, self-limited illness

### Erythema Infectiosum (Fifth Disease)

#### Virology
- **Virus**: Parvovirus B19
- **Age**: School-age children
- **Transmission**: Respiratory droplets
- **Incubation**: 4-14 days

#### Clinical Presentation
- **Prodrome**: Mild fever, malaise (may be absent)
- **Facial rash**: "Slapped cheek" appearance
- **Body rash**: Lacy, reticular rash on trunk and extremities
- **Duration**: Rash may wax and wane for weeks
- **Arthralgia**: Common in adolescents and adults

#### Complications
- **Aplastic crisis**: In patients with hemolytic anemias (sickle cell)
- **Hydrops fetalis**: If infection during pregnancy
- **Arthritis**: Usually self-limited

#### Management
- **Supportive care**: Antipyretics, analgesics
- **Not contagious**: Once rash appears, no longer infectious
- **Pregnancy**: Counsel pregnant contacts to seek evaluation

### Hand-Foot-Mouth Disease

#### Virology
- **Virus**: Coxsackievirus A16, Enterovirus 71
- **Age**: Young children, daycare/preschool
- **Transmission**: Fecal-oral, respiratory droplets
- **Incubation**: 3-7 days

#### Clinical Presentation
- **Prodrome**: Fever, sore throat, malaise
- **Oral lesions**: Painful vesicles on tongue, buccal mucosa, palate
- **Rash**: Maculopapular → vesicular on hands, feet, buttocks
- **Duration**: Resolves in 7-10 days

#### Complications
- **Dehydration**: From painful oral lesions
- **Viral meningitis**: Uncommon
- **Myocarditis**: Rare with EV71

#### Management
- **Supportive care**: Fluids, soft diet, pain control
- **Mouth care**: Salt water rinses, topical analgesics
- **Infection control**: Contagious during illness and weeks after

### Scarlet Fever

#### Bacteriology
- **Organism**: Group A Streptococcus (GAS)
- **Toxin**: Erythrogenic toxin
- **Associated with**: Strep pharyngitis

#### Clinical Presentation
- **Pharyngitis**: Sore throat, fever, headache
- **Rash**: Fine, sandpaper-like texture
- **Distribution**: Trunk, groin, axillae (spares palms/soles)
- **Pastia lines**: Petechiae in skin folds
- **Strawberry tongue**: Initially white, then red and bumpy
- **Desquamation**: Peeling of fingers and toes after rash resolves

#### Diagnosis
- **Rapid strep test**: Quick diagnosis
- **Throat culture**: Gold standard
- **Clinical**: Classic presentation

#### Management
- **Antibiotics**: Penicillin or amoxicillin
- **Supportive care**: Antipyretics, fluids
- **Return to school**: 24 hours after antibiotics started

#### Complications
- **Acute rheumatic fever**: Prevented by appropriate antibiotic treatment
- **Post-streptococcal glomerulonephritis**: Not prevented by antibiotics
- **Suppurative**: Peritonsillar abscess, cervical lymphadenitis

## Upper Respiratory Infections

### Common Cold (Viral URI)

#### Virology
- **Viruses**: Rhinovirus (most common), coronavirus, adenovirus, RSV
- **Transmission**: Respiratory droplets, direct contact
- **Incubation**: 1-3 days

#### Clinical Presentation
- **Nasal symptoms**: Rhinorrhea (clear → purulent), congestion
- **Throat symptoms**: Sore throat, mild pharyngeal erythema
- **Systemic symptoms**: Low-grade fever, malaise
- **Cough**: Often develops as illness progresses
- **Duration**: 7-10 days (can last up to 2 weeks)

#### Management
- **Supportive care**: Primary treatment
- **Hydration**: Encourage fluid intake
- **Saline nasal drops**: For congestion in infants
- **Humidification**: May provide comfort
- **Antipyretics**: For fever/discomfort
- **Avoid**: Antibiotics (viral illness), aspirin in children, cough suppressants <4 years

### Pharyngitis

#### Etiology
- **Viral**: Most common (70-85%)
- **Bacterial**: Group A Streptococcus (15-30%)
- **Other bacteria**: Group C/G strep, Arcanobacterium, Mycoplasma

#### Clinical Presentation

##### Viral Pharyngitis
- **Gradual onset**: Associated URI symptoms
- **Conjunctivitis**: Suggests adenovirus
- **Hoarseness**: Laryngeal involvement
- **Exanthem**: Various viral rashes

##### Streptococcal Pharyngitis
- **Acute onset**: Sudden sore throat, fever
- **Absence of cough**: Suggestive of strep
- **Pharyngeal erythema**: Red throat with exudate
- **Palatal petechiae**: Small red spots on soft palate
- **Tender adenopathy**: Anterior cervical lymph nodes
- **Scarlatiniform rash**: Scarlet fever

#### Diagnosis
- **Clinical**: Modified Centor criteria
- **Rapid antigen test**: Quick, high specificity
- **Throat culture**: Gold standard, indicated if rapid test negative
- **Not indicated**: ASO titers for acute diagnosis

#### Management
- **Viral**: Supportive care only
- **Streptococcal**:
  - Penicillin V or amoxicillin (10 days)
  - Cephalexin if penicillin allergy
  - Azithromycin if severe penicillin allergy
- **Supportive**: Analgesics, fluids, soft foods
- **Return to school**: 24 hours after antibiotics started

### Otitis Media

#### Classification
- **Acute otitis media (AOM)**: Acute infection of middle ear
- **Otitis media with effusion (OME)**: Fluid without infection
- **Chronic suppurative otitis media**: Persistent infection with perforation

#### Risk Factors
- **Age**: 6-24 months (peak incidence)
- **Daycare attendance**: Increased exposure
- **Tobacco smoke**: Secondhand smoke exposure
- **Bottle feeding**: Lack of breastfeeding
- **Craniofacial abnormalities**: Cleft palate
- **Immunodeficiency**: Recurrent infections

#### Microbiology
- **Streptococcus pneumoniae**: 30-40%
- **Haemophilus influenzae**: 20-30%
- **Moraxella catarrhalis**: 10-15%
- **Viral**: 20-40% (often co-infection)

#### Clinical Presentation
- **Ear pain**: Otalgia, pulling at ear in infants
- **Fever**: Variable, may be absent
- **Irritability**: Especially in young children
- **Hearing loss**: Temporary conductive hearing loss
- **Associated symptoms**: URI symptoms often present

#### Diagnosis
- **Otoscopy**: Essential for diagnosis
- **Bulging TM**: Most important finding
- **Erythema**: Alone not diagnostic
- **Impaired mobility**: Pneumatic otoscopy
- **Effusion**: Presence of middle ear fluid

#### Management

##### Observation vs. Antibiotics
- **Criteria for observation** (if reliable follow-up):
  - Age ≥6 months with non-severe illness
  - Unilateral AOM in 6-23 months
  - Otorrhea absent
- **Immediate antibiotics**:
  - Age <6 months
  - Bilateral AOM in <2 years
  - Severe symptoms
  - Immunocompromised

##### Antibiotic Selection
- **First-line**: Amoxicillin 80-90 mg/kg/day
- **Failure**: Amoxicillin-clavulanate
- **Penicillin allergy**: Cephalosporins, macrolides
- **Duration**: 10 days (<2 years), 5-7 days (≥2 years)

##### Supportive Care
- **Analgesia**: Acetaminophen or ibuprofen
- **Decongestants**: Not recommended
- **Antihistamines**: Not beneficial

#### Complications
- **Tympanic membrane perforation**: Otorrhea
- **Mastoiditis**: Tenderness, swelling behind ear
- **Intracranial**: Meningitis, brain abscess (rare)
- **Hearing loss**: Usually temporary

### Sinusitis

#### Classification
- **Acute bacterial sinusitis**: <30 days
- **Subacute**: 30-90 days
- **Chronic**: >90 days
- **Recurrent acute**: ≥4 episodes per year

#### Predisposing Factors
- **Viral URI**: Precedes bacterial sinusitis
- **Allergic rhinitis**: Mucosal inflammation
- **Anatomic abnormalities**: Deviated septum, polyps
- **Ciliary dysfunction**: Cystic fibrosis, primary ciliary dyskinesia
- **Immunodeficiency**: Recurrent infections

#### Clinical Presentation
- **Persistent symptoms**: URI symptoms >10 days without improvement
- **Severe symptoms**: High fever (≥39°C), purulent discharge ≥3 days
- **Worsening symptoms**: Biphasic pattern (worsening after improvement)
- **Facial pain**: Maxillary or frontal tenderness
- **Headache**: Frontal or periorbital
- **Cough**: Often worse at night

#### Diagnosis
- **Clinical**: Based on symptoms and duration
- **Imaging**: Not routinely indicated
- **Transillumination**: Not reliable in children
- **Cultures**: Not routinely obtained

#### Management
- **Watchful waiting**: Mild symptoms, reliable follow-up
- **Antibiotics**: Persistent, severe, or worsening symptoms
  - Amoxicillin-clavulanate (first-line)
  - Cephalosporins (alternative)
  - Duration: 10-14 days
- **Supportive care**: Saline irrigation, analgesics, humidification
- **Intranasal steroids**: May help in allergic rhinitis

#### Complications
- **Orbital cellulitis**: Periorbital swelling, vision changes
- **Intracranial**: Meningitis, epidural abscess, cavernous sinus thrombosis
- **Osteomyelitis**: Frontal bone involvement

## Lower Respiratory Infections

### Bronchiolitis

#### Virology
- **RSV**: 50-80% of cases
- **Other viruses**: Rhinovirus, influenza, parainfluenza, adenovirus, metapneumovirus
- **Season**: Winter months (November-March in Northern Hemisphere)
- **Age**: Peak incidence 2-6 months

#### Risk Factors for Severe Disease
- **Prematurity**: <37 weeks gestation
- **Chronic lung disease**: BPD
- **Congenital heart disease**: Hemodynamically significant
- **Immunodeficiency**: Compromised immunity
- **Age**: <12 weeks
- **Neuromuscular disease**: Impaired clearance

#### Clinical Presentation
- **Prodrome**: URI symptoms 1-3 days (rhinorrhea, cough)
- **Lower respiratory symptoms**: Tachypnea, retractions, wheezing
- **Hypoxemia**: Oxygen saturation <90%
- **Feeding difficulties**: Poor feeding, dehydration
- **Apnea**: Especially in young infants

#### Diagnosis
- **Clinical**: Based on age, season, symptoms
- **Viral testing**: Not routinely necessary, may guide cohorting
- **Chest x-ray**: Not routinely indicated
- **Pulse oximetry**: Monitor oxygenation

#### Management
- **Supportive care**: Mainstay of treatment
- **Hydration**: IV fluids if unable to maintain oral intake
- **Oxygen**: Supplemental oxygen for hypoxemia
- **Suctioning**: Nasal suctioning for comfort
- **Not effective**: Bronchodilators, corticosteroids, antibiotics (unless secondary infection)
- **Hospitalization**: Severe respiratory distress, hypoxemia, dehydration, apnea

#### Prevention
- **Palivizumab**: Monoclonal antibody for high-risk infants
- **Hand hygiene**: Important infection control measure
- **Breastfeeding**: Protective effect
- **Avoid exposure**: Tobacco smoke, sick contacts

### Pneumonia

#### Classification
- **Community-acquired**: Most common
- **Nosocomial**: Hospital-acquired
- **Aspiration**: Foreign material into lungs
- **Opportunistic**: In immunocompromised

#### Etiology by Age

##### Newborn to 3 Months
- **Bacterial**: Group B Strep, E. coli, Listeria
- **Viral**: RSV, influenza, parainfluenza
- **Atypical**: Chlamydia trachomatis

##### 3 Months to 5 Years
- **Viral**: RSV, influenza, parainfluenza, adenovirus (most common)
- **Bacterial**: S. pneumoniae, H. influenzae
- **Atypical**: Mycoplasma (rare at this age)

##### School-Age and Adolescents
- **Bacterial**: S. pneumoniae, M. pneumoniae
- **Atypical**: Mycoplasma, Chlamydophila pneumoniae
- **Viral**: Influenza, adenovirus

#### Clinical Presentation

##### Bacterial Pneumonia
- **Abrupt onset**: High fever, chills
- **Cough**: Productive (older children)
- **Respiratory distress**: Tachypnea, retractions
- **Chest pain**: Pleuritic pain
- **Auscultation**: Crackles, decreased breath sounds

##### Atypical Pneumonia
- **Gradual onset**: Low-grade fever
- **Nonproductive cough**: Persistent dry cough
- **Systemic symptoms**: Headache, myalgia
- **Auscultation**: May be normal despite x-ray findings

##### Viral Pneumonia
- **Preceding URI**: Recent upper respiratory symptoms
- **Low-grade fever**: May be absent
- **Wheezing**: Bronchiolitis-like presentation
- **Bilateral findings**: Diffuse involvement

#### Diagnosis
- **Clinical**: Fever + respiratory symptoms + tachypnea
- **Chest x-ray**: Not always necessary for outpatient management
- **Laboratory**: CBC, CRP (not specific)
- **Microbiologic**: Blood culture (severe cases), sputum culture (older children)

#### Management

##### Outpatient Treatment
- **Age >3 months**: Amoxicillin 90 mg/kg/day
- **Atypical coverage**: Add azithromycin if >5 years with atypical features
- **Follow-up**: 48-72 hours to ensure improvement

##### Inpatient Treatment
- **Moderate severity**: Ampicillin or ceftriaxone
- **Severe/complicated**: Ceftriaxone + vancomycin
- **Atypical**: Add azithromycin
- **Duration**: 7-10 days total

##### Supportive Care
- **Oxygen**: Maintain SpO2 >90%
- **Hydration**: IV fluids if needed
- **Antipyretics**: Fever management
- **Chest physiotherapy**: Not beneficial

#### Complications
- **Pleural effusion**: Para-pneumonic effusion
- **Empyema**: Purulent pleural fluid
- **Lung abscess**: Necrotizing pneumonia
- **Pneumothorax**: Air leak

### Croup (Laryngotracheobronchitis)

#### Virology
- **Parainfluenza**: 75% of cases
- **Other viruses**: Influenza, RSV, adenovirus, rhinovirus
- **Age**: 6 months to 3 years (peak 2 years)
- **Season**: Fall and winter

#### Clinical Presentation
- **Prodrome**: URI symptoms 1-2 days
- **Barky cough**: "Seal-like" or "barking" cough
- **Stridor**: Inspiratory stridor (worse at night)
- **Hoarseness**: From laryngeal inflammation
- **Fever**: Usually low-grade

#### Severity Assessment (Westley Score)
- **Mild**: No stridor at rest, minimal retractions
- **Moderate**: Stridor at rest, moderate retractions
- **Severe**: Stridor and retractions at rest, agitation, lethargy

#### Management

##### Mild Croup
- **Cool mist**: Traditional (limited evidence)
- **Observation**: Monitor for worsening
- **Dexamethasone**: 0.6 mg/kg PO × 1 dose

##### Moderate to Severe Croup
- **Dexamethasone**: 0.6 mg/kg (PO, IM, or IV)
- **Racemic epinephrine**: Nebulized for severe stridor
- **Observation**: 2-4 hours after epinephrine
- **Oxygen**: If hypoxic
- **Hospitalization**: Severe distress, recurrent epinephrine needs

#### Complications
- **Respiratory failure**: Rare with treatment
- **Bacterial tracheitis**: Rare, severe superinfection

## Gastrointestinal Infections

### Viral Gastroenteritis

#### Virology
- **Rotavirus**: Previously most common (decreased with vaccination)
- **Norovirus**: Most common cause currently
- **Adenovirus**: Year-round occurrence
- **Astrovirus**: Mild illness

#### Clinical Presentation
- **Vomiting**: Often first symptom, may be prominent
- **Diarrhea**: Watery, non-bloody
- **Fever**: Variable
- **Abdominal pain**: Cramping
- **Duration**: 3-7 days (rotavirus may last longer)

#### Assessment
- **Dehydration**: Primary concern
- **Vital signs**: Heart rate, blood pressure
- **Weight loss**: Best indicator of dehydration
- **Physical exam**: Skin turgor, capillary refill, mucous membranes

#### Management
- **Oral rehydration**: Preferred for mild-moderate dehydration
- **ORS composition**: Sodium 45-90 mEq/L, glucose
- **IV fluids**: Severe dehydration, intractable vomiting
- **Diet**: Continue regular diet as tolerated (no BRAT diet)
- **Medications**: Generally avoid antidiarrheals, antiemetics

### Bacterial Gastroenteritis

#### Common Bacterial Causes
- **Salmonella**: Non-typhoidal
- **Shigella**: Dysentery
- **Campylobacter**: Most common bacterial cause
- **E. coli**: Various pathogenic strains (EHEC, ETEC, EIEC)
- **C. difficile**: Antibiotic-associated

#### Clinical Presentation
- **Dysentery**: Bloody, mucoid stools (Shigella, EHEC, Campylobacter)
- **Fever**: Often high-grade
- **Abdominal pain**: Severe cramping
- **Systemic symptoms**: Headache, myalgia

#### Diagnosis
- **Stool culture**: Indicated for bloody diarrhea, severe illness, immunocompromised
- **Stool studies**: Leukocytes, occult blood
- **C. difficile toxin**: If antibiotic exposure

#### Management
- **Hydration**: Primary treatment
- **Antibiotics**: Selective use
  - **Shigella**: Azithromycin, ceftriaxone
  - **Campylobacter**: Azithromycin if severe
  - **Salmonella**: Generally avoid (prolongs carrier state) except in specific situations
  - **EHEC**: Avoid (may increase HUS risk)
- **Infection control**: Hand hygiene, isolation

## Key Points

- Immunizations have dramatically reduced vaccine-preventable diseases but require high coverage for herd immunity
- Most pediatric respiratory infections are viral and do not require antibiotics
- Pertussis remains a threat, especially to young infants; cocooning strategy protects newborns
- Measles is highly contagious; recognize by prodrome of 3 C's, Koplik spots, and cephalocaudal rash
- Distinguishing viral from bacterial pharyngitis prevents unnecessary antibiotic use
- Acute otitis media diagnosis requires bulging tympanic membrane; observation is appropriate in select cases
- Bronchiolitis is supportive care only; bronchodilators and steroids are not effective
- Pneumonia treatment depends on age and likely pathogen; atypical organisms more common in school-age
- Croup responds well to corticosteroids; racemic epinephrine for severe cases
- Gastroenteritis management focuses on hydration; antibiotics rarely indicated
- Hand hygiene is the single most important infection prevention measure
- Antimicrobial stewardship is essential to combat resistance in pediatric populations

## References

1. Centers for Disease Control and Prevention. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2024. MMWR. 2024;73(1).
2. American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd Edition. Itasca, IL: American Academy of Pediatrics; 2021.
3. Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76.
4. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013;131(3):e964-e999.
5. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502.
